Lenacapavir, recently approved by the US FDA, represents a significant advancement in HIV treatment, particularly for multidrug-resistant strains. Developed by Gilead Sciences, this twice-yearly injectable has shown promising results in global clinical trials, effectively reducing viral loads.
However, its high cost poses a challenge for widespread access, especially in low-income regions heavily affected by HIV, prompting calls for global collaboration and funding to improve accessibility to this crucial treatment.
